The Company Is on Track to Complete the Interim Data Analysis Before the End of Q1 2025 and to Submit the Findings to the U.S. Food and Drug Administration (FDA) Philadelphia, Pennsylvania--(Newsfile ...

Paradigm Biopharmaceuticals has selected Advanced Clinical as the clinical research organisation (CRO) to support its pivotal ...

For Tammy Gusher Delgado, 56, the decision to join a clinical trial was clear. With a recent multiple sclerosis diagnosis and a clinical trial offering either the study drug or an approved ...

Paradigm Biopharmaceuticals has selected Advanced Clinical as the preferred clinical research organisation for the phase III ...

Phase I clinical trials are the first step in testing a new treatment or combination of treatments. These trials often ...

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic ...

Compelling Patient Response Highlighted by Stable Disease and Significant Reduction in Blast Count After One Treatment Cycle HOUSTON, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ ...

The E.mbrace study is a randomized, double-blind, placebo-controlled, multicenter, interventional phase 3 study evaluating the efficacy, safety, and immunogenicity of a single dose of the vaccine ...

The FIRCE-1 trial investigating the CAR T-cell therapy firi-cel in relapsed/refractory large B-cell lymphoma has been ...

Vistagen Therapeutics' Q3 2025 earnings reveal progress on Phase 3 trials for social anxiety drug fasedienol, innovative therapies, and strong ...

The trial will evaluate the safety and effectiveness of a next-generation vaccine administered through a nasal spray or ...